---
title: BCM Breast Cancer Trials
markmap:
  initialExpandLevel: 3
  maxWidth: 200
  colorFreezeLevel: 6
---
- CLOSED
  - Adjuvant
    - HR POS
      - NO LINE
        - **MA39**
          
             - [x] Newly Diagnosis of IDC w/ no metastisis 
          Treated with BCS or Mastectomy with no residual disease 
  - Peri-Surgical
    - NO GROUP
      - NO LINE
        - **CHEST**
          
             - [x] Undergoing Mastectomy + Reconstruction 
  - Presurgical
    - NO GROUP
      - NO LINE
        - **ATUSA-iSONO**
          
             - [x] Women with a suspected breast lesion in one of both breasts
          
          
             - [x] Disease T1c or larger 
- MED ONC
  - Adjuvant
    - NO GROUP
      - NO LINE
        - MK-2870 [OPENING 05/2026]
          
             - [x] Have residual Disease post NACT
    - HER2
      - NO LINE
        - **FLAMINGO -01**
          
             - [x] Stage I/II with nonpCR OR stage III (pCR or not) to be enorlled <90 days from completion of HP/TDM1
          
          
             - [x] TWO cohorst depending on HLA-A-02
        - **ICE COMPRESS / SWOG S2205**
          
             - [x] NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).
          
          
             - [x] Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's
        - **FLEX**
          
             - [x] T1 to T3, with smallest size 6mm. Any N
        - **ADEPT [CLOSED 03/2026]**
          
             - [x] ER+ OR PR+ with HER2+ disease T1A/B/C. N1mi allowed. 
          
          
             - [x] No more than 8 weeks of ET
    - HR POS
      - NO LINE
        - **ICE COMPRESS / SWOG S2205**
          
             - [x] NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).
          
          
             - [x] Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's
        - **OFSET (NRG BR009)**
          
             - [x] ER+ (>1%) HER2- with pT1-3 pN0-1. 
          
          
             - [x] RS N1 <26. RS N0 21-25. RS N0 16-20 WITH T minimum at 30mm (G1), 20mm (G2) or 10mm (G3)
        - **FLEX**
          
             - [x] T1 to T3, with smallest size 6mm. Any N
        - **ELEGANT**
          
             - [x] ER+ High Risk (Defined by trial) between year 2 and 5 of adjuvant ET +/- CDK4/6i or PARPi
    - TNBC
      - NO LINE
        - **ICE COMPRESS / SWOG S2205**
          
             - [x] NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).
          
          
             - [x] Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's
        - **OptimICE-PCR**
          
             - [x] TNBC (ER/PR <10%)  T1cN1-2 or T2-4N0-2 with ypT0 OR ypTis
          
          
             - [x] Adju RT  and Pembro, followed by registration
        - **FLEX**
          
             - [x] T1 to T3, with smallest size 6mm. Any N
  - Metastatic
    - NO GROUP
      - 1
        - OPERA-02 [OPENING Fall 2026]
          
             - [x] DeNovo or recurrent in 1st Line using Palazestrant
      - 2
        - TRAILBLASER
          
             - [x] Progression post 1st Line
        - **Bicycle-201**
          
             - [x] Received minimum of 1 chemo therapy in the metastatic setting, up to three chemo lines
          
          
             - [x] NECTIN4 amplification required. Around 60% of Pts
      - 3
        - Verastem [OPENING 04/2026]
          
             - [x] Prior progression on CDK4/6i AND Fulvestrant
          
          
             - [x] No more than 2 chemo lines
        - **Bicycle-201**
          
             - [x] Received Endocrine therapy (no limits) and a minimum of 1 chemo therapy in the metastatic setting, up to three chemo lines
          
          
             - [x] NECTIN4 amplification required. Around 60% of Pts
        - **Bicycle-201**
          
             - [x] Received minimum of 1 chemo therapy in the metastatic setting, up to three chemo lines
          
          
             - [x] NECTIN4 amplification required. Around 60% of Pts
      - 4
        - Verastem [OPENING 04/2026]
          
             - [x] Prior progression on CDK4/6i AND Fulvestrant
          
          
             - [x] No more than 2 chemo lines
        - **Bicycle-201**
          
             - [x] Received Endocrine therapy (no limits) and a minimum of 1 chemo therapy in the metastatic setting, up to three chemo lines
          
          
             - [x] NECTIN4 amplification required. Around 60% of Pts
        - **Bicycle-201**
          
             - [x] Received minimum of 1 chemo therapy in the metastatic setting, up to three chemo lines
          
          
             - [x] NECTIN4 amplification required. Around 60% of Pts
      - 5
        - **Bicycle-201**
          
             - [x] Received Endocrine therapy (no limits) and a minimum of 1 chemo therapy in the metastatic setting, up to three chemo lines
          
          
             - [x] NECTIN4 amplification required. Around 60% of Pts
    - HER2
      - 2
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
      - 3
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
      - 4
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
    - HR POS
      - 1
        - **EvoPAR-Breast01**
          
             - [x] DenoVo metastatic opr 1ry resistant ER+ (>1%)
          
          
             - [x] BRCA1/2 OR PALB2 (either germline or somatic) 
      - 2
        - **ELAINE-III**
          
             - [x] Progression on 1st Line CDK4/6. ESR1 mutation
          
          
             - [x] No priot Abema in adjuvant or metastatic setting
        - **OPERA-1 [CLOSED 06/2026]**
          
             - [x] Post 1st Line progression while on ET/CDK , adjuvant ET or within 2 years post ET. No prior Chemo in Stage 4. 
          
          
             - [x] Part A three arm for OP 120, OP 90 and SoC. Part B is OP vs SoC [Faslo or AI]
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
        - **TBCRC 064**
          
             - [x] IHC 0/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2
          
          
             - [x] ER+ HER2- must have progressed on or within 12 months of adjuvant ET, OR got minimum of 1L of ET (including prior CDK4/6)
        - **QuantifyHER**
          
             - [x] ER+ IHC 1+ who will start Enhertu (Or within 30 days after starting)
          
          
             - [x] Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible
      - 3
        - **OPERA-1 [CLOSED 06/2026]**
          
             - [x] Post 2 Lines Line of ET, lasting at least 6 months. No prior Chemo in Stage 4. 
          
          
             - [x] Part A three arm for OP 120, OP 90 and SoC. Part B is OP vs SoC [Faslo or AI]
          
          
             - [x] If 2nd line was Faslo, 3rd line SoC can be AI
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
        - **TBCRC 064**
          
             - [x] IHC 0/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2
          
          
             - [x] Received 1st Line ET (including CDK4/6i), 2nd Line,
        - **QuantifyHER**
          
             - [x] ER+ IHC 1+ who will start Enhertu (Or within 30 days after starting)
          
          
             - [x] Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible
      - 4
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
        - **TBCRC 064**
          
             - [x] IHC 0/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2
          
          
             - [x] Received 1st Line ET (including CDK4/6i), 2nd Line, and on 3rd Line ADC. Can join directly to ADC2 at 4th L from Dato or Enhertu
        - **QuantifyHER**
          
             - [x] ER+ IHC 1+ who will start Enhertu (Or within 30 days after starting)
          
          
             - [x] Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible
      - NO LINE
        - NCBRE [OPENING Fall 2026]
          
             - [x] ILC ER+ PR+ HER2- with ERBB2 mutation.
          
          
             - [x] T1c (Min size 15mm) N0/N1/N2
    - TNBC
      - 1
        - **TBCRC 061**
          
             - [x] Receipt of Immunotherapy in the advanced setting
        - **TBCRC 064**
          
             - [x] IHC 0+/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2
          
          
             - [x] TNBC Strict 0-1 prior lines.
      - 2
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
        - **TBCRC 061**
          
             - [x] Receipt of Immunotherapy in the advanced setting
        - **TBCRC 064**
          
             - [x] IHC 0+/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2
          
          
             - [x] TNBC Strict 0-1 prior lines, but can join from Enhertu 2L to Dato
        - **QuantifyHER**
          
             - [x] ER- IHC 1+ who will start Enhertu (Or within 30 days after starting)
          
          
             - [x] Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible"
      - 3
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
        - **TBCRC 061**
          
             - [x] Receipt of Immunotherapy in the advanced setting
        - **TBCRC 064**
          
             - [x] IHC 0+/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2
          
          
             - [x] TNBC Strict 0-1 prior lines, but can join from Enhertu 2L to Dato
        - **QuantifyHER**
          
             - [x] ER- IHC 1+ who will start Enhertu (Or within 30 days after starting)
          
          
             - [x] Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible"
      - 4
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
  - Neoadjuvant
    - HER2
      - NO LINE
        - **RESPONSE**
          
             - [x] 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers
          
          
             - [x] Will receive weekly Taxol HP  with ddAC
        - **ICE COMPRESS / SWOG S2205**
          
             - [x] NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).
          
          
             - [x] Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's
        - **FLEX**
          
             - [x] T1 to T3, with smallest size 6mm. Any N
    - HR POS
      - NO LINE
        - **RESPONSE**
          
             - [x] 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers
          
          
             - [x] High Risk ER+ (Grade III, Age <50, ER < 6/8 OR Ki67 >29%). Will receive weekly Taxol with ddAC
        - **EVANGELINE [CLOSING 08/2026]**
          
             - [x] Clinical T2 or T3 and N0 or N1 with Grade I and II
          
          
             - [x] ER+ 67% or more, Allred 6-8
        - **ICE COMPRESS / SWOG S2205**
          
             - [x] NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).
          
          
             - [x] Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's
        - **S2206**
          
             - [x] Stage II and III, including IBC. ER+ or PR+ per CAP (>1%)
          
          
             - [x] High 2 on MP
        - **FLEX**
          
             - [x] T1 to T3, with smallest size 6mm. Any N
    - TNBC
      - NO LINE
        - **RESPONSE**
          
             - [x] 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers
          
          
             - [x] Will receive weekly Taxol with ddAC (Pembro added if indicated, Carbo added if T3)
        - **ICE COMPRESS / SWOG S2205**
          
             - [x] NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).
          
          
             - [x] Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's
        - **S2212**
          
             - [x] TNBC (ER/PR <5%) with T2-T4 N0 OR T1-T3 N1-N2. Randomized to either KN522 versus Taxotere Carbo  Pembro x 6 Cycles
          
          
             - [x] No Stage IIIC, IIIB T4 N+ OR IBC
        - **FLEX**
          
             - [x] T1 to T3, with smallest size 6mm. Any N
        - **TNBC ctDNA Tissue Banking**
          
             - [x] TNBC Stage II/III receiving NACT (+/- ICB)
          
          
             - [x] ctDNA collected after Taxol and after AC, both before definitive surgery
- Med Onc
  - Metastatic
    - NO GROUP
      - 2
        - EVOLVE-DBT
          
- RAD ONC
  - Postsurgical
    - NO GROUP
      - NO LINE
        - PREDICT II
          
             - [x] Dx of DCIS w/ tumor size <6cm
          
          
             - [x] Eligible for BCS, radiation and/or systemic treatment
- SURG ONC
  - Peri-Surgical
    - NO GROUP
      - NO LINE
        - **Breast ATLAS**
          
             - [x] Undergoing PPX Mastectomy
        - **PRECISION**
          
             - [x] Dx of DCIS and/or IDC undergoing BCS or mastectomy
          
          
             - [x] No hx of prior therapy treatment
        - **SentiNot 2.0**
          
             - [x] Pre-operative diagnosis of DCIS or other suspicious lesion not confirmed to be invasive breast cancer
          
          
             - [x] Willing to forgo initial SLNB and have SLNB as a later second procedure if DCIS is upgraded to invasive cancer
        - **Magellan**
          
             - [x] Non-metastatic patients with node positive breast cancer (cT0-4, N1)
          
          
             - [x] Magseed placement prior to NAC
  - Postsurgical
    - HR POS
      - NO LINE
        - **LoTAM**
          
             - [x] Stage 1 and 2A (T < 30mm, N0) ER+ (>10%) HER2- Breast Cancer
          
          
             - [x] LOW Genomic risk (MP LOW, RS <26 OR ProSigna <40)
  - Presurgical
    - NO GROUP
      - NO LINE
        - **BCM TISSUE COLLECTION**
          
             - [x] Suspicious lesion receiving an U/S guided biopsy with birads 4b-5
        - **ANGEL**
          
             - [x] Any suspicious lesion receiving a biopsy